Clinical and experimental studies indicate that Gal-3 is crucial for the microglial response to the pathology of AD and that overexpression of Gal-3 may alter amyloid plaque aggregation and increase plaque-associated toxicity. This evidence concerns the gene LGALS3 and amyloidosis.